Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4

被引:0
作者
Oskola, E. V. [1 ]
Shubina, A. T. [1 ]
Karpov, Yu. A. [1 ]
机构
[1] Inst Clin Cardiol, Moscow, Russia
关键词
angioprotection; type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitors; incretins; DEPENDENT INSULINOTROPIC POLYPEPTIDE; TYPE-2; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE RELEASE; CARDIOVASCULAR SAFETY; ENDOTHELIAL FUNCTION; GLYCEMIC CONTROL; ADIPOSE-TISSUE; SITAGLIPTIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is a major health problem in all developed countries. It contributes to the development of atherosclerosis and increases the risk of cardiovascular events so blood glucose level correction is essential to preventing these complications. The relatively new and promising class of anti-diabetic drugs is dipeptidyl peptidase-4 inhibitors. By improving carbohydrate metabolism, they have angioprotective effects, such as anti-inflammatory and anti-atherosclerotic ones, including atherosclerotic plaque stabilization, improve endothelial function, lower blood pressure, and reduce the severity of albuminuria, which may have clinical implications for the prevention of macrovascular complications of type 2 DM.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
[41]   Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin [J].
Andrea D. Fass ;
Jennifer A. Gershman .
Advances in Therapy, 2013, 30 :337-353
[42]   Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors [J].
Gumprecht, Janusz .
CLINICAL DIABETOLOGY, 2015, 4 (06) :238-242
[43]   Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus [J].
Davidson, Michael H. .
POSTGRADUATE MEDICINE, 2014, 126 (03) :56-65
[44]   Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review [J].
Deacon, C. F. .
DIABETES OBESITY & METABOLISM, 2011, 13 (01) :7-18
[45]   Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis [J].
Liu, Xin ;
Men, Peng ;
Wang, Yuhui ;
Zhai, Suodi ;
Liu, George .
LIPIDS IN HEALTH AND DISEASE, 2016, 15 :1-9
[46]   Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure [J].
Kankanala, Saumya Reddy ;
Syed, Rafay ;
Gong, Quan ;
Ren, Boxu ;
Rao, Xiaoquan ;
Zhong, Jixin .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (05) :2450-2458
[47]   Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms [J].
Yang, Yinqiu ;
Zhao, Chenhe ;
Liang, Jing ;
Yu, Mingxiang ;
Qu, Xinhua .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[48]   Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes [J].
Koska, Juraj ;
Sands, Michelle ;
Burciu, Camelia ;
Reaven, Peter .
DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (03) :154-163
[49]   Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety [J].
Matteucci, E. ;
Giampietro, O. .
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (31) :4753-4760